File failed to load: https://mathjax.xml-journal.net/platformTools/js/MathJax-master/config/TeX-AMS-MML_SVG.js
中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Menu
Volume 41 Issue 2
Feb.  2025
Turn off MathJax
Article Contents
Abstract
References
Article Navigation >  Journal of Clinical Hepatology  > 2025  >  41(2): 221-227

Research advances in the disease burden of viral hepatitis in China

DOI: 10.12449/JCH250205
  • 1.

    National Center for AIDS/STD Control and Prevention，Chinese Center for Disease Control and Prevention，Beijing 102206，China

  • 2.

    National Immunization Program，Chinese Center for Disease Control and Prevention，Beijing 100050，China

  • 3.

    Technical Office，WHO China Office，Beijing 100600，China

  • 4.

    National Center for Chronic and Noncommunicable Disease Control and Prevention，Chinese Center for Disease Control and Prevention，Beijing 100050，China

  • 5.

    Maternal and Child Health Center，National Health Commission，Beijing 100081，China

  • 6.

    National Cancer Center/Cancer Hospital，Chinese Academy of Medical Sciences，Beijing 100021，China

  • 7.

    Liver Research Center，Beijing Friendship Hospital，Capital Medical University，Beijing 100050，China

  • 8.

    School of Health Management and Policy，Peking Union Medical College，Beijing 100730，China

  • 9.

    Chinese Foundation for Hepatitis Prevention and Treatment，Beijing 100106，China

More Information
  • Corresponding author: WANG Yu， wangyu@chinacdc.cn （ORCID： 0000-0002-7891-4633）
  • Received Date: 2024-11-30
  • Accepted Date: 2025-01-13
  • Published Date: 2025-02-25
    Abstract
  • Over the past three decades， China has made significant progress in the prevention and control of viral hepatitis， and the incidence rates of new-onset pediatric hepatitis B virus infections and acute viral hepatitis in the population have reduced to a relatively low level； however， there is still a heavy disease burden of chronic viral hepatitis in China， which severely affects the health status of the population. This study systematically summarizes the achievements of viral hepatitis prevention and control in China， analyzes existing problems and challenges， and proposes comprehensive prevention and control strategies and measures to eliminate viral hepatitis as a public health threat based on the national conditions of China， in order to provide a reference for related departments in China on how to achieve the action targets for eliminating viral hepatitis as a public health threat by 2030.

     

    • FullText(HTML)
  • 致谢: 感谢王华庆、王潇滟、乔建荣、任明辉、庄辉、李增德、周脉耕、郑徽、徐小元、梁晓峰等专家对本文撰写提供的支持和帮助。
    • References(25)
  • [1]
    World Health Organization. Global health sector strategy on viral hepatitis 2016- 2021[EB/OL].( 2016-06)[ 2024-06-22]. https//www.who.int/hepatitis/strategy2016-2021/ghss-hep/en/. https//www.who.int/hepatitis/strategy2016-2021/ghss-hep/en/
    [2]
    National Health and Family Planning Commission, National Development and Reform Commission, Ministry of Education, et al. Notice on the issuance of Action plan for the prevention and treatment of viral hepatitis in China by National Administration of Traditional Chinese Medicine(2017—2020)[J]. Gazette of the State Council of the People’s Republic of China, 2018,( 7): 76- 82.

    国家计生卫生委, 国家发展改革委, 教育部, 等. 中医药局关于印发中国病毒性肝炎防治规划(2017-2020年)的通知[J]. 中华人民共和国国务院公报, 2018,( 7): 76- 82.
    [3]
    National Health Commission of the People’s Republic of China. Action plan for eliminating hepatitis C as a public health threat( 2021- 2030 年)[EB/OL].( 2021-08-31)[ 2024-06-22]. http://www.nhc.gov.cn/jkj/s3586/202109/c462ec94e6d14d8291c5309406603153.shtml?R0NMKk6uozOC=1654310439640. http://www.nhc.gov.cn/jkj/s3586/202109/c462ec94e6d14d8291c5309406603153.shtml?R0NMKk6uozOC=1654310439640

    国家卫生健康委员会. 消除丙型肝炎公共卫生危害行动工作方案( 2021- 2030 年)[EB/OL].( 2021-08-31)[ 2024-06-22]. http://www.nhc.gov.cn/jkj/s3586/202109/c462ec94e6d14d8291c5309406603153.shtml?R0NMKk6uozOC=1654310439640. http://www.nhc.gov.cn/jkj/s3586/202109/c462ec94e6d14d8291c5309406603153.shtml?R0NMKk6uozOC=1654310439640
    [4]
    General Office of National Health and Family Planning Commission, General Office of Ministry of Finance. Notice on the implementation of nucleic acid testing in blood stations[EB/OL].( 2015-03-02)[ 2024-06-22]. http://www.nhc.gov.cn/yzygj/s3589/201503/a93bcfaca8b04f2bbaa7eef064a8d522.shtml. http://www.nhc.gov.cn/yzygj/s3589/201503/a93bcfaca8b04f2bbaa7eef064a8d522.shtml

    国家卫生计生委办公厅, 财政部办公厅. 关于做好血站核酸检测工作的通知[EB/OL].( 2015-03-02)[ 2024-06-22]. http://www.nhc.gov.cn/yzygj/s3589/201503/a93bcfaca8b04f2bbaa7eef064a8d522.shtml. http://www.nhc.gov.cn/yzygj/s3589/201503/a93bcfaca8b04f2bbaa7eef064a8d522.shtml
    [5]
    XU JJ, HAN MJ, JIANG YJ, et al. Prevention and control of HIV/AIDS in China: Lessons from the past three decades[J]. Chin Med J(Engl), 2021, 134( 23): 2799- 2809. DOI: 10.1097/CM9.0000000000001842.
    [6]
    FU HC, XU J, ZHOU C, et al. Progress of community-based methadone maintenance treatment in China from 2004 to 2021[J]. Chin J AIDS STD, 2023, 29( 1): 28- 32. DOI: 10.13419/j.cnki.aids.2023.01.06.

    付鸿臣, 徐杰, 周楚, 等. 2004—2021年全国社区美沙酮维持治疗工作进展分析[J]. 中国艾滋病性病, 2023, 29( 1): 28- 32. DOI: 10.13419/j.cnki.aids.2023.01.06.
    [7]
    TANG L, LIU QQ, WANG XQ, et al. Interrupted time series analyses of hepatitis A incidence in different endemic areas of China before and after introduction of hepatitis A vaccine into the national Expanded Program on Immunization[J]. Chin J Vaccines Immun, 2022, 28( 1): 19- 25. DOI: 10.19914/j.CJVI.2022005.

    唐林, 刘倩倩, 王晓琪, 等. 中国扩大国家免疫规划前后不同流行区甲型肝炎报告发病率变化的中断时间序列分析[J]. 中国疫苗和免疫, 2022, 28( 1): 19- 25. DOI: 10.19914/j.CJVI.2022005.
    [8]
    Disease Prevention and Control Bureau, National Health Commission of the People’s Republic of China. An overview of national notifiable infectious diseases in 2021[EB/OL].( 2022-04-22)[ 2024-11-19]. http://www.nhc.gov.cn/jkj/s3578/202204/4fd88a291d914abf8f7a91f6333567e1.shtml. http://www.nhc.gov.cn/jkj/s3578/202204/4fd88a291d914abf8f7a91f6333567e1.shtml

    国家卫生健康委员会疾病预防控制局. 2021年全国法定传染病疫情概况[EB/OL].( 2022-04-22)[ 2024-11-19]. http://www.nhc.gov.cn/jkj/s3578/202204/4fd88a291d914abf8f7a91f6333567e1.shtml. http://www.nhc.gov.cn/jkj/s3578/202204/4fd88a291d914abf8f7a91f6333567e1.shtml
    [9]
    WANG FZ, ZHENG H, SUN XJ, et al. Achievements and prospects for hepatitis B prevention and control in China[J]. Chin J Vaccines Immun, 2019, 25( 5): 487- 492. DOI: 10.19914/j.cjvi.2019.05.001.

    王富珍, 郑徽, 孙校金, 等. 中国控制乙型病毒性肝炎的成就与展望[J]. 中国疫苗和免疫, 2019, 25( 5): 487- 492. DOI: 10.19914/j.cjvi.2019.05.001.
    [10]
    ZHENG H, WANG Y, WANG FZ, et al. New progress in HBV control and the cascade of health care for people living with HBV in China: Evidence from the fourth national serological survey, 2020[J]. Lancet Reg Health West Pac, 2024, 51: 101193. DOI: 10.1016/j.lanwpc.2024.101193.
    [11]
    ZHAO XY, LI M, WANG H, et al. Impact of national centralized drug procurement policy on antiviral utilization and expenditure for hepatitis B in China[J]. J Clin Transl Hepatol, 2022, 10( 3): 420- 428. DOI: 10.14218/JCTH.2022.00167.
    [12]
    ZENG HM, CHEN WQ, ZHENG RS, et al. Changing cancer survival in China during 2003-15: A pooled analysis of 17 population-based cancer registries[J]. Lancet Glob Health, 2018, 6( 5): e555- e567. DOI: 10.1016/S2214-109X(18)30127-X.
    [13]
    HE J, CHEN WQ. China cancer registry annual report[M]. Beijing: People’s Medical Publishing House, 2018.

    赫捷, 陈万青. 2017中国肿瘤登记年报[M]. 北京: 人民卫生出版社, 2018.
    [14]
    WANG SM, ZHENG RS, HAN BF, et al. Age distribution of cancer incidence and mortality in China in 2022[J]. China Cancer, 2024, 33( 3): 165- 174. DOI: 10.11735/j.issn.1004-0242.2024.03.A001.

    王少明, 郑荣寿, 韩冰峰, 等. 2022年中国人群恶性肿瘤发病与死亡年龄特征分析[J]. 中国肿瘤, 2024, 33( 3): 165- 174. DOI: 10.11735/j.issn.1004-0242.2024.03.A001.
    [15]
    WANG XX, LIU HX, QI JL, et al. Trends in mortality of cirrhosis in China: An analysis of the China death surveillance database from 2008 to 2020[J]. J Clin Transl Hepatol, 2024, 12( 3): 236- 244. DOI: 10.14218/JCTH.2023.00454.
    [16]
    ZHENG RS, CHEN R, HAN BF, et al. Cancer incidence and mortality in China, 2022[J]. Chin J Oncol, 2024, 46( 3): 221- 231. DOI: 10.3760/cma.j.cn112152-20240119-00035.

    郑荣寿, 陈茹, 韩冰峰, 等. 2022年中国恶性肿瘤流行情况分析[J]. 中华肿瘤杂志, 2024, 46( 3): 221- 231. DOI: 10.3760/cma.j.cn112152-20240119-00035.
    [17]
    QI JL, LI ML, WANG LJ, et al. National and subnational trends in cancer burden in China, 2005-20: An analysis of national mortality surveillance data[J]. Lancet Public Health, 2023, 8( 12): e943- e955. DOI: 10.1016/S2468-2667(23)00211-6.
    [18]
    LIU Y, ZHENG JX, HAO JL, et al. Global burden of primary liver cancer by five etiologies and global prediction by 2035 based on global burden of disease study 2019[J]. Cancer Med, 2022, 11( 5): 1310- 1323. DOI: 10.1002/cam4.4551.
    [19]
    WANG X, LIN SX, TAO J, et al. Study of liver cirrhosis over ten consecutive years in Southern China[J]. World J Gastroenterol, 2014, 20( 37): 13546- 13555. DOI: 10.3748/wjg.v20.i37.13546.
    [20]
    WANG MJ, WANG YT, FENG XS, et al. Contribution of hepatitis B virus and hepatitis C virus to liver cancer in China north areas: Experience of the Chinese National Cancer Center[J]. Int J Infect Dis, 2017, 65: 15- 21. DOI: 10.1016/j.ijid.2017.09.003.
    [21]
    QIN SK. Interim report of China Liver Cancer Survey(CLCS)[C]. The 22nd National Congress of Clinical Oncology and 2019 CSCO Academic Conference, Xiamen, 2019.

    秦叔逵. 中国原发性肝癌临床登记调查(CLCS)的中期报告[C]. 第22届全国临床肿瘤学大会暨2019年CSCO学术会议, 厦门, 2019.
    [22]
    National Health Commission of the People’s Republic of China. China Health Yearbook 2022[EB/OL].( 2023-05-17)[ 2024-06-22]. http://www.nhc.gov.cn/mohwsbwstjxxzx/tjtjnj/202305/6ef68aac6bd14c1eb9375e01a0faa1fb/files/b05b3d958fc546d98261d165cea4adba.pdf. http://www.nhc.gov.cn/mohwsbwstjxxzx/tjtjnj/202305/6ef68aac6bd14c1eb9375e01a0faa1fb/files/b05b3d958fc546d98261d165cea4adba.pdf

    国家卫生健康委员会. 2022中国卫生健康统计年鉴[EB/OL].( 2023-05-17)[ 2024-06-22]. http://www.nhc.gov.cn/mohwsbwstjxxzx/tjtjnj/202305/6ef68aac6bd14c1eb9375e01a0faa1fb/files/b05b3d958fc546d98261d165cea4adba.pdf. http://www.nhc.gov.cn/mohwsbwstjxxzx/tjtjnj/202305/6ef68aac6bd14c1eb9375e01a0faa1fb/files/b05b3d958fc546d98261d165cea4adba.pdf
    [23]
    HAN MJ, CHEN QF, XU P, et al. Striving for the new journey of AIDS prevention and control during the 13th Five-Year Plan: Retrospects and prospects of AIDS prevention and control in China[J]. Chin J AIDS STD, 2021, 27( 12): 1327- 1331. DOI: 10.13419/j.cnki.aids.2021.12.01.

    韩孟杰, 陈清峰, 徐鹏, 等. 砥砺奋进“十三五”艾滋病防控迈向新征程: 我国艾滋病防治回顾与展望[J]. 中国艾滋病性病, 2021, 27( 12): 1327- 1331. DOI: 10.13419/j.cnki.aids.2021.12.01.
    [24]
    XIAO HP. New advances in the prevention and treatment of tuberculosis[M]. Shanghai: Fudan University Press, 2004.

    肖和平. 结核病防治新进展[M]. 上海: 复旦大学出版社, 2004.
    [25]
    World Health Organization. Global tuberculosis report 2020[EB/OL].( 2022-10-14)[ 2024-11-21]. https://iris.who.int/bitstream/handle/10665/336069/9789240013131-eng.pdf?sequence=1. https://iris.who.int/bitstream/handle/10665/336069/9789240013131-eng.pdf?sequence=1
    • Relative Articles

  • Relative Articles

    [1]Jian LI, Zhongfu LIU. Advances， achievements， and challenges in action to eliminate hepatitis C as a public health threat in China[J]. Journal of Clinical Hepatology, 2025, 41(2): 216-220. doi: 10.12449/JCH250204
    [2]Yu WANG. Public health management strategies： A pathway to eliminating viral hepatitis threats[J]. Journal of Clinical Hepatology, 2025, 41(2): 201-204. doi: 10.12449/JCH250201
    [3]Shanshan LIU, Xiaohui YU, Jianwei CAI. Changing trend of the disease burden of liver cirrhosis in China from 1990 to 2019[J]. Journal of Clinical Hepatology, 2024, 40(4): 726-733. doi: 10.12449/JCH240414
    [4]Hongqiao ZHENG, Ailing WANG. Advances and challenges in eliminating mother-to-child transmission of hepatitis B virus worldwide[J]. Journal of Clinical Hepatology, 2024, 40(11): 2152-2157. doi: 10.12449/JCH241104
    [5]Huawei QIU, Tianfu LIANG, Zhi ZHONG, Xuejiao JIA, Yang JIANG. Trend and prediction of the disease burden of acute hepatitis B in China[J]. Journal of Clinical Hepatology, 2023, 39(11): 2575-2579. doi: 10.3969/j.issn.1001-5256.2023.11.010
    [6]Fuqiang CUI. Global elimination of viral hepatitis as a public health threat: Promoting diagnosis and treatment is the key to reducing mortality[J]. Journal of Clinical Hepatology, 2021, 37(7): 1522-1524. doi: 10.3969/j.issn.1001-5256.2021.07.006
    [7]Branch of Hepatobiliary Diseases, Chinese Association of Chinese Medicine. The standards of traditional Chinese medicine syndrome differentiation for viral hepatitis[J]. Journal of Clinical Hepatology, 2017, 33(10): 1839-1846. doi: 10.3969/j.issn.1001-5256.2017.10.002
    [8]Yao HongYu, Wang YuTing, Tang HongPing, Huang HuiYao, Zhang HongJian, Sha ChunXia, Shi JuFang, Dai Min, Chen TaoYang, Qu ChunFeng. Economic burden of inpatients with hepatitis B virus infection-related diseases and its impact on family financial status in Qidong, Jiangsu Province, China[J]. Journal of Clinical Hepatology, 2017, 33(5): 853-859. doi: 10.3969/j.issn.1001-5256.2017.05.012
    [9]Jin XueYuan, Lou Min, Zhao Ping, Long SuYun. Clinical significance of the serum neopterin detection in patients with chronic viral hepatitis[J]. Journal of Clinical Hepatology, 2007, 23(2): 90-91.
    [11]Tao Hu, Gao Tao, Xu Bin. Revaluate the clinical significance of serum transferrin changes in patients with hepatitis[J]. Journal of Clinical Hepatology, 2004, 20(3): 148-149.
    [12]Zhang Min, Zhang LingXia, Xin ShaoJie, Zhao JingMin, Wang SongShan, Wang LinJie. The relationship between transforming growth factor β1 and liver fibrosis[J]. Journal of Clinical Hepatology, 2000, 16(1): 32-33.
    [13]He DongGou, Chen BoMing, Lin YongPing. Research of T lymphocyte subtypes and the phagocytosis activity of macrophages in the patients with virul hepatitis[J]. Journal of Clinical Hepatology, 2000, 16(1): 30-31.
    • Supplements(0)
    • Cited By
  • 加载中
    Created with Highcharts 5.0.7Chart context menuAccess Class DistributionFULLTEXT: 3.0 %FULLTEXT: 3.0 %META: 94.7 %META: 94.7 %PDF: 2.3 %PDF: 2.3 %FULLTEXTMETAPDF
    Created with Highcharts 5.0.7Chart context menuAccess Area Distribution其他: 2.3 %其他: 2.3 %三明: 3.2 %三明: 3.2 %上海: 0.5 %上海: 0.5 %东莞: 0.2 %东莞: 0.2 %中卫: 0.5 %中卫: 0.5 %丽水: 0.9 %丽水: 0.9 %仙桃: 0.6 %仙桃: 0.6 %六安: 0.2 %六安: 0.2 %内江: 0.1 %内江: 0.1 %包头: 0.2 %包头: 0.2 %北京: 0.9 %北京: 0.9 %南京: 0.4 %南京: 0.4 %南宁: 0.1 %南宁: 0.1 %南平: 0.8 %南平: 0.8 %南昌: 0.2 %南昌: 0.2 %南通: 0.4 %南通: 0.4 %厦门: 0.5 %厦门: 0.5 %台州: 0.2 %台州: 0.2 %合肥: 0.5 %合肥: 0.5 %呼伦贝尔: 0.1 %呼伦贝尔: 0.1 %咸宁: 0.4 %咸宁: 0.4 %哥伦布: 0.1 %哥伦布: 0.1 %唐山: 0.3 %唐山: 0.3 %嘉兴: 2.7 %嘉兴: 2.7 %大连: 3.4 %大连: 3.4 %太原: 0.1 %太原: 0.1 %威海: 3.1 %威海: 3.1 %娄底: 0.2 %娄底: 0.2 %孝感: 0.2 %孝感: 0.2 %宁德: 0.9 %宁德: 0.9 %宿迁: 6.9 %宿迁: 6.9 %山景城: 0.2 %山景城: 0.2 %广州: 1.5 %广州: 1.5 %张家口: 0.9 %张家口: 0.9 %徐州: 0.5 %徐州: 0.5 %德阳: 0.3 %德阳: 0.3 %怀化: 0.1 %怀化: 0.1 %恩施: 0.3 %恩施: 0.3 %成都: 0.1 %成都: 0.1 %扬州: 1.3 %扬州: 1.3 %文昌: 1.1 %文昌: 1.1 %无锡: 0.4 %无锡: 0.4 %朝阳: 0.1 %朝阳: 0.1 %杭州: 2.4 %杭州: 2.4 %武汉: 0.2 %武汉: 0.2 %汕头: 0.4 %汕头: 0.4 %江门: 0.5 %江门: 0.5 %池州: 0.9 %池州: 0.9 %沈阳: 1.2 %沈阳: 1.2 %泉州: 0.4 %泉州: 0.4 %泸州: 1.6 %泸州: 1.6 %济南: 0.2 %济南: 0.2 %淮北: 0.9 %淮北: 0.9 %淮南: 1.2 %淮南: 1.2 %淮安: 0.2 %淮安: 0.2 %深圳: 0.2 %深圳: 0.2 %温州: 1.3 %温州: 1.3 %渭南: 0.2 %渭南: 0.2 %湖州: 2.5 %湖州: 2.5 %漯河: 0.2 %漯河: 0.2 %漳州: 2.1 %漳州: 2.1 %潜江: 0.8 %潜江: 0.8 %濮阳: 0.1 %濮阳: 0.1 %烟台: 0.5 %烟台: 0.5 %珠海: 2.0 %珠海: 2.0 %盘锦: 0.1 %盘锦: 0.1 %石家庄: 0.6 %石家庄: 0.6 %福州: 2.5 %福州: 2.5 %福建省: 0.1 %福建省: 0.1 %科泽科德: 0.1 %科泽科德: 0.1 %绍兴: 0.2 %绍兴: 0.2 %自贡: 2.2 %自贡: 2.2 %舟山: 4.9 %舟山: 4.9 %芒廷维尤: 1.4 %芒廷维尤: 1.4 %芝加哥: 0.5 %芝加哥: 0.5 %苏州: 2.2 %苏州: 2.2 %荆门: 0.8 %荆门: 0.8 %莆田: 1.1 %莆田: 1.1 %莱芜: 1.6 %莱芜: 1.6 %葫芦岛: 2.1 %葫芦岛: 2.1 %蚌埠: 0.2 %蚌埠: 0.2 %衢州: 1.0 %衢州: 1.0 %襄阳: 0.5 %襄阳: 0.5 %西宁: 0.5 %西宁: 0.5 %西安: 0.2 %西安: 0.2 %诺沃克: 0.1 %诺沃克: 0.1 %贵阳: 0.1 %贵阳: 0.1 %赣州: 0.1 %赣州: 0.1 %辽阳: 0.2 %辽阳: 0.2 %运城: 0.2 %运城: 0.2 %郑州: 0.1 %郑州: 0.1 %重庆: 1.4 %重庆: 1.4 %金华: 3.8 %金华: 3.8 %铜川: 0.2 %铜川: 0.2 %锦州: 0.7 %锦州: 0.7 %镇江: 3.2 %镇江: 3.2 %长春: 2.7 %长春: 2.7 %长沙: 0.1 %长沙: 0.1 %随州: 1.2 %随州: 1.2 %鞍山: 1.7 %鞍山: 1.7 %马鞍山: 0.1 %马鞍山: 0.1 %鹰潭: 1.3 %鹰潭: 1.3 %黄冈: 1.0 %黄冈: 1.0 %黄南: 0.5 %黄南: 0.5 %黄石: 0.7 %黄石: 0.7 %龙岩: 0.2 %龙岩: 0.2 %其他三明上海东莞中卫丽水仙桃六安内江包头北京南京南宁南平南昌南通厦门台州合肥呼伦贝尔咸宁哥伦布唐山嘉兴大连太原威海娄底孝感宁德宿迁山景城广州张家口徐州德阳怀化恩施成都扬州文昌无锡朝阳杭州武汉汕头江门池州沈阳泉州泸州济南淮北淮南淮安深圳温州渭南湖州漯河漳州潜江濮阳烟台珠海盘锦石家庄福州福建省科泽科德绍兴自贡舟山芒廷维尤芝加哥苏州荆门莆田莱芜葫芦岛蚌埠衢州襄阳西宁西安诺沃克贵阳赣州辽阳运城郑州重庆金华铜川锦州镇江长春长沙随州鞍山马鞍山鹰潭黄冈黄南黄石龙岩

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(4)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (1134) PDF downloads(29) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[3520]YesterdayPV[6428]TodayIP[1357]TodayPV[1918]Online[115]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return